The role of pharmaceutical raw materials Dabrafenib

On May 29, 2013, the United States food and drug administration (FDA) has approved a new drug Dabrafenib (Tafinlar) and used in the treatment of metastatic melanoma patients of surgical treatment of melanoma. Darla who (dabrafenib) is the FDA after d he had (vemurafenib), including the single resistance (may be) after the approval of the third drug for the treatment of metastatic melanoma.

Use the drug that need to be detected before the BRAF V600E mutation, the drug is not used for the BRAF wild-type melanoma. In an international multicenter, randomized, open label, controlled trial, 250 cases of BRAF V600E dabrafenib divided by 3:1 positive melanoma patients in treatment group and of kappa oxazine (dacarbazine) treatment group. Results show that the dabrafenib treatment group median progression-free surial was 5.1 months, up to kappa oxazine treatment group median progression-free surial was 3.5 months.